The Analyst · 2013 · 49 citations · 35 references
Life SciencesBiotechnologyOncologyBiosensorsNanobiotechnologyNanomaterialsAntibody-antigen RecognitionBiosensors For Immune DetectionNanomaterial-based BiosensorsNanoparticle-based ImmunotechnologyTumor AntigensTumor MarkersAntigen-antibody InteractionsCancer Antigen 125Gold NanostructuresMethod Detection LimitNanomaterial-based ImmunosensorsNanoparticle-based ImmunoassaysNanorodsPlasmonic Nanorods
Cancer antigen 125 (CA 125) is a useful tumor marker with a threshold value of 35 U mL(-1) expressed by more than 80% of patients with non-mucinous epithelial ovarian cancer. In this work, a novel strategy for the analysis of CA 125 using the plasmon resonance scattering (PRS) properties of gold nanorods was proposed. The gold nanorod (GNR)-anti-CA 125 conjugates were prepared first. The immunoreaction between the GNR modified CA 125 antibody and CA 125 took place in aqueous solution after the addition of CA 125. The target protein concentration was determined by analyzing the level of GNR aggregation caused by CA 125 antibody-antigen interactions using PRS. At a concentration of 1.0-80 U mL(-1), CA 125 could be determined with a detection limit of 0.4 U mL(-1). The PRS immunosensor showed high sensitivity, selectivity, and reproducibility. Determination of CA 125 in serum samples showed good recovery.
35
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth M. Ward et al. · CA A Cancer Journal for Clinicians · 2006 · 5.3K citations · Full text
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Robert C. Bast, Maryellen Feeney, Herbert Lazarus et al. · Journal of Clinical Investigation · 1981 · 1.7K citations · Full text
Medicine, Cancer Biology, Oncology +17